A detailed history of Captrust Financial Advisors transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 15,322 shares of INKT stock, worth $7,967. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,322
Previous 35,729 57.12%
Holding current value
$7,967
Previous $33,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.74 - $1.14 $15,101 - $23,263
-20,407 Reduced 57.12%
15,322 $11,000
Q2 2024

Aug 14, 2024

SELL
$0.87 - $1.56 $16,148 - $28,956
-18,562 Reduced 34.19%
35,729 $33,000
Q4 2023

Feb 14, 2024

SELL
$0.88 - $1.21 $6,607 - $9,084
-7,508 Reduced 12.15%
54,291 $58,000
Q3 2023

Nov 14, 2023

BUY
$1.1 - $2.09 $24,482 - $46,517
22,257 Added 56.29%
61,799 $67,000
Q2 2023

Aug 14, 2023

BUY
$0.89 - $3.33 $35,192 - $131,674
39,542 New
39,542 $83,000

Others Institutions Holding INKT

About MiNK Therapeutics, Inc.


  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $17.6M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.